A new documentary film by AIDS-Free World: The drugs Bedaquiline and Delamanid can mean the difference between life and death for people suffering from the worst and most noxious strain of tuberculosis in the world, MDR-TB. The government of India has restricted access to the drugs for its 140,000 MDR-TB sufferers. South Africa has made a different choice for 20,000 MDR-TB patients. The consequences are profound.
Low- and middle-income countries (LMICs) face a range of obstacles in healthcare including access, funding, education, and personnel. However, laboratory diagnostics including pathology are particularly challenging because of the specialized personnel, unique reagents, quality processes, and overall logistics of delivering the right diagnosis to the right patient at the right time.
Connecting research capacity with the needs of countries, communities, NGOs, and companies poses a challenge and an opportunity. To address this, we have created an online platform where funded or unfunded research questions are posted. We hope this site, which can be found in the "Resources" ribbon on our website, will connect researchers, especially Masters, PhD, or post doc candidates with those requiring high quality research.
Post research questions or view these opportunities here.
American University of Antigua (AUA) College of Medicine’s Global MD Program is conducted in collaboration with Florida International University (FIU). As one of the most innovative and recognized Caribbean medical schools, AUA plays a pivotal role in addressing the world’s forecasted shortage of physicians, with key accreditations required for medical licensure throughout the United States, the United Kingdom, Canada, and India.
The past decades have witnessed significant strides in global health, yet around two thirds of total deaths worldwide are attributed to preventable and treatable diseases, with the highest burden found in low- and middle-income countries (LMICs) and among women and children. Innovative approaches and technologies play a vital role in saving lives, improving overall health outcomes around the world and achieving the sustainable development goals (SDGs).
The END Fund is the only private philanthropic initiative solely dedicated to ending the five most common neglected tropical diseases (NTDs), which affect more than 1.5 billion people globally. It efficiently puts private capital to work, advocating for NTD programs that are innovative, integrated, and cost-effective. It facilitates strong partnerships with the private sector and aims to support national disease control programs in over 29 countries.